EyePoint reaches full DME enrollment with $222.5m and a runway ending near the readout

EyePoint, Inc. (Nasdaq: EYPT) has completed enrollment in both pivotal Phase 3 trials of DURAVYU for diabetic macular edema, moving its six-month retinal treatment strategy into a fully recruited program of more than 480 patients. The COMO and CAPRI studies finished enrollment within five months, ahead of the company’s previous third-quarter target, with 56-week results expected in the fourth quarter of 2027. EyePoint shares traded near $12.86 on July 30, up approximately 7.7%, giving the company a market capitalization of about $1.1 billion. The operational achievement reduces recruitment risk, but it also begins a long follow-up period during which EyePoint must finance two diabetic macular edema trials, prepare for possible wet age-related macular degeneration development decisions and continue scaling its commercial manufacturing capabilities. The financial tension is that EyePoint’s last reported runway extended into the fourth quarter of 2027, the same quarter in which the diabetic macular edema results are expected.

Rapid enrollment lowers execution risk but does not prove six-month disease control

COMO and CAPRI are global, randomized, double-masked Phase 3 trials comparing the 2.7 mg DURAVYU intravitreal insert with on-label 2 mg aflibercept. The studies include both treatment-naive patients and people who previously received therapy for diabetic macular edema, giving EyePoint an opportunity to test the product across a broader clinical population than the small Phase 2 program. Participants assigned to DURAVYU will be treated every six months.

The primary endpoint is the blended change from baseline in best-corrected visual acuity at weeks 52 and 56. The trials use a non-inferiority design, meaning DURAVYU does not need to produce greater average visual improvement than aflibercept. It must show that less frequent treatment does not result in a clinically unacceptable reduction in vision compared with the established control.

That design gives EyePoint a commercially relevant path because the product’s intended value lies primarily in durability. A treatment delivered twice a year could still become important even if visual outcomes are broadly similar to aflibercept, provided it substantially reduces injections, clinic visits and rescue treatment.

The secondary endpoints will determine whether the durability claim is clinically convincing. COMO and CAPRI will measure safety, anatomical retinal outcomes, reduction in treatment burden and the percentage of eyes that remain free from supplemental aflibercept injections. A technically positive non-inferiority result could be less commercially persuasive if a large proportion of patients require rescue injections before their next scheduled DURAVYU dose.

EyePoint has not publicly disclosed the numerical non-inferiority margin in the July 30 announcement. That threshold will matter when results are released because a study may meet its formal statistical objective even when the control arm has a numerical visual advantage, as long as the difference remains within the agreed boundary.

Rapid recruitment nonetheless carries meaningful business value. Slow enrollment can delay clinical readouts, extend operating losses and force biotechnology companies to raise capital before reaching important data. Completing both trials in five months gives EyePoint greater confidence in its fourth-quarter 2027 timetable and demonstrates that its investigator network can recruit hundreds of retinal patients across multiple countries.

Many sites involved in EyePoint’s wet age-related macular degeneration program also participated in COMO and CAPRI. Reusing an established network should reduce site-startup work and allow investigators already familiar with DURAVYU administration, safety monitoring and supplemental-treatment rules to support the second pivotal program more efficiently.

Enrollment completion should therefore be viewed as a reduction in operational uncertainty rather than a clinical catalyst. The major value question remains whether vorolanib exposure is strong enough near the end of each six-month interval to preserve both retinal anatomy and vision without frequent supplemental therapy.

August wet AMD data could determine how investors value the later DME opportunity

DURAVYU is also being evaluated in the fully enrolled LUGANO and LUCIA Phase 3 trials for wet age-related macular degeneration. More than 900 patients were randomized across those studies, and EyePoint now expects the first wet AMD topline results beginning in August 2026.

Those results will arrive more than a year before the diabetic macular edema readout and may become the most important near-term test of EyePoint’s platform. Both programs use the same 2.7 mg vorolanib insert, the same bioerodible Durasert E delivery technology and a similar six-month redosing strategy. A positive wet AMD result would provide large-scale evidence that the insert can deliver durable intraocular exposure safely across repeated doses.

Success in wet AMD would not guarantee success in diabetic macular edema. The diseases involve different patient populations and biological processes, while diabetic macular edema may involve inflammation and metabolic vascular injury in addition to VEGF-mediated leakage. EyePoint argues that vorolanib may address several pathways through intracellular inhibition of VEGF receptors, platelet-derived growth factor receptors and IL-6/JAK1 inflammatory signaling, but the full clinical importance of that multi-mechanism profile remains unproven in Phase 3.

The wet AMD data could nevertheless reshape the financial and strategic context for COMO and CAPRI. A positive pivotal result may raise EyePoint’s stock price, strengthen its access to capital and support commercial-partnership discussions before the DME studies report. An unfavorable result could weaken confidence in the shared delivery system and make financing the remaining DME follow-up more difficult.

The two-indication structure creates significant operating leverage if DURAVYU succeeds. EyePoint can manufacture one core product, use one delivery platform and build commercial relationships with the same retinal specialists across wet AMD and diabetic macular edema. Physician education, distribution, manufacturing quality systems and post-approval safety monitoring could support both indications rather than being created separately.

That same concentration creates platform risk. DURAVYU is EyePoint’s dominant development asset, and both pivotal programs depend on the same molecule, insert and six-month durability thesis. A safety issue involving inflammation, insert behavior or repeated dosing could affect confidence across the entire franchise, even if it first emerges in only one disease.

EyePoint reported that a May 2026 independent safety review covering its ongoing wet AMD and diabetic macular edema Phase 3 programs recommended continuation without protocol changes. DURAVYU had been evaluated in more than 190 patients across four completed studies without an observed product-related safety signal, according to the company. Masked safety reviews and limited earlier trials remain less informative than the complete unmasked Phase 3 datasets that will eventually support regulatory decisions.

EyePoint’s cash runway reaches the planned readout quarter but leaves little room for delay

EyePoint reported $222.5 million in cash, cash equivalents and marketable securities as of March 31, 2026. Management said those resources were expected to fund operations into the fourth quarter of 2027, beyond the wet AMD data and into the period when the diabetic macular edema results are scheduled.

That runway creates a narrow margin. The company used $80.5 million of operating cash during the first quarter, compared with $53.1 million a year earlier. EyePoint also recorded a quarterly net loss of $84.8 million, nearly double the $45.2 million loss reported in the prior-year period.

Research and development expenses reached $72.1 million, including $46.9 million directly attributed to DURAVYU. The increase was driven by the simultaneous wet AMD and diabetic macular edema Phase 3 trials and the scale-up of EyePoint’s Northbridge manufacturing facility. General and administrative expenses reached $15.2 million.

Completing enrollment should gradually reduce some clinical-site and recruitment expenses, but substantial costs will continue. The company must maintain study follow-up, provide treatment and rescue medication, perform imaging assessments, monitor safety, clean data and prepare regulatory-quality analyses. It must also continue manufacturing work and launch preparation if the earlier wet AMD results are positive.

EyePoint raised approximately $5.7 million in gross proceeds through its at-the-market facility during April and May by selling 385,395 shares at a weighted average price of $14.75. That activity shows the company is willing to supplement its balance sheet through incremental equity issuance even before the major Phase 3 catalysts.

EyePoint had approximately 83.8 million common shares outstanding as of May 1 and another 2.6 million pre-funded warrants outstanding at the end of March. Additional equity financing would increase dilution, although favorable wet AMD data could allow the company to raise money at a stronger valuation than would be available after disappointing results.

The financial position is stronger than that of many clinical-stage biotechnology companies, but the runway should not be interpreted as eliminating capital risk. A delay of several months in the DME readout, higher launch-preparation spending or a regulatory request for additional wet AMD work could move the required financing date forward.

A successful August wet AMD result could also accelerate spending. EyePoint has appointed a chief commercial officer and operates a commercial manufacturing facility in Northbridge, Massachusetts. Positive pivotal data would likely prompt greater investment in regulatory submissions, inventory, quality systems, market access and a retinal sales infrastructure before approval generates revenue.

The market capitalization of approximately $1.1 billion already reflects considerable expectations for DURAVYU. Investors are not valuing the company solely on its cash balance. The current valuation incorporates the possibility that the platform becomes a commercial franchise across two large retinal indications, making the stock highly sensitive to the upcoming wet AMD data.

Six-month dosing must stand out in a market where competitors already offer longer intervals

The commercial standard is moving beyond monthly anti-VEGF injections. Standard 2 mg aflibercept, which serves as the control in COMO and CAPRI, is generally administered monthly for five initial doses and then every eight weeks in diabetic macular edema, although some patients require more frequent treatment.

Regeneron’s 8 mg Eylea HD formulation can be administered every eight to 16 weeks following three initial monthly doses, and intervals of up to 20 weeks may be considered after one year in appropriately responding patients. Roche’s Vabysmo also offers flexible extended dosing for some diabetic macular edema patients. These options mean that DURAVYU must compete against an increasingly durable standard rather than only against monthly treatment.

Roche’s Susvimo provides another long-duration approach through a surgically implanted ocular delivery system for patients who previously responded to anti-VEGF injections. DURAVYU’s proposed differentiation is that it would use a standard office-based intravitreal injection rather than a permanent surgically implanted device.

Two planned treatments per year would still represent a meaningful reduction relative to most current regimens. The advantage will be strongest if a majority of patients remain rescue-free for the full six months and if repeated inserts continue to provide predictable release without inflammation or other ocular complications.

DURAVYU also needs to demonstrate practical advantages beyond scheduled dosing. Retinal physicians will consider whether the solid insert is easy to administer, whether it behaves consistently inside the eye and how complications would be managed if sustained drug exposure produces an adverse reaction.

Pricing and reimbursement will depend on the complete value proposition. A durable product may command premium pricing if it prevents missed treatments, reduces clinic capacity requirements and preserves vision in patients who struggle with frequent appointments. Payers may resist a high upfront cost when approved biologics and biosimilars already offer effective disease control.

EyePoint’s business case is therefore not built solely on a six-month label. Commercial adoption will depend on vision outcomes, rescue-injection rates, retinal anatomy, safety, administration convenience and economics compared with increasingly durable competitors.

Completing COMO and CAPRI enrollment ahead of schedule removes one important source of risk. It does not resolve whether DURAVYU can produce the consistent late-interval disease control required to become a major diabetic macular edema product. Before that question is answered in late 2027, the August wet AMD results will determine whether EyePoint approaches the next stage with a validated platform and stronger financing leverage or with a more difficult capital and development outlook.

Key takeaways from DURAVYU’s completed DME enrollment and EyePoint’s outlook

• EyePoint enrolled more than 480 patients across COMO and CAPRI within five months, completing both Phase 3 diabetic macular edema trials ahead of its previous schedule.
• The studies compare 2.7 mg DURAVYU every six months with on-label 2 mg aflibercept and are expected to report 56-week results in the fourth quarter of 2027.
• Non-inferiority in visual acuity is the primary objective, but rescue-injection rates and retinal anatomy will determine whether the six-month dosing claim is commercially convincing.
• EyePoint shares gained approximately 7.7% on July 30, lifting the company’s market capitalization to about $1.1 billion.
• Phase 3 wet AMD data are expected beginning in August 2026 and could validate or weaken confidence in the same DURAVYU insert well before the DME readout.
• EyePoint reported $222.5 million in cash and investments at March 31, with a runway extending into the fourth quarter of 2027, approximately when the DME results are planned.
• First-quarter operating cash use reached $80.5 million, while the net loss increased to $84.8 million as Phase 3 and manufacturing spending accelerated.
• EyePoint sold $5.7 million of stock through its at-the-market facility during April and May, demonstrating that additional equity remains part of its financing strategy.
• DURAVYU must differentiate itself from Eylea HD, Vabysmo and Susvimo in a retinal market where longer treatment intervals are already available.
• The investment case now depends on whether EyePoint can turn strong trial execution into positive wet AMD data, maintain sufficient capital and eventually show that twice-yearly DME treatment preserves vision without frequent rescue injections.